Alcoholic diffuse hepatic steatosis (ADHS) is a progressive liver disease. The disease is characterized by increased fatty content and is caused by high levels of fat in the liver. The risk of death is increased for patients with non-alcoholic steatohepatitis.
The most common cause of alcoholic diffuse hepatic steatotic liver is diabetes. During diabetes, insulin increases hepatic glucose levels, which lead to adiponectin release. In addition, insulin stimulates the production of fatty acids. The liver receives 30% of its blood supply from the portal vein and 70% from the hepatic artery. The portal vein has tributaries in the splenic vein, inferior mesenteric vein, and right gastric vein. These veins empty directly into the portal vein.
A study by Nobili V and Manco M published in the journal World J Gastroenterol in 2001 found that a non-invasive marker, SteatoTest, was associated with hepatocyte fibrosis in non-alcoholic fatty liver disease. Although this disease has several associated symptoms, the condition is considered reversible. The underlying cause must be removed to reverse its progression.
A contrast-enhanced MRI scan may be helpful in identifying a steatosis. An MRI scan may also show multiple fatty lesions outside the parenchyma of the liver. This can make it difficult to distinguish between a steatotic and non-steatotic liver.